

# **Humira Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Branded, Biosimilar), By Application (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis (UC), Ankylosing Spondylitis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition, 2020-2030F**

<https://marketpublishers.com/r/HA8131C57B47EN.html>

Date: July 2025

Pages: 184

Price: US\$ 4,500.00 (Single User License)

ID: HA8131C57B47EN

## **Abstracts**

### Market Overview

The Global Humira Market was valued at USD 10.41 Billion in 2024 and is projected to reach USD 19.84 Billion by 2030, growing at a CAGR of 11.32% during the forecast period. The market is witnessing steady growth, fueled by the increasing prevalence of autoimmune and chronic inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. With a growing elderly population and improved awareness around early diagnosis and treatment, biologic therapies like Humira (adalimumab) are being prescribed more frequently. Humira's proven effectiveness in reducing inflammation and improving long-term disease management has made it a preferred treatment across various specialties, including rheumatology, gastroenterology, and dermatology. Additionally, its usage is being extended through clinical trials exploring new indications and combination therapies. Despite the expiration of key patents, the brand continues to maintain a strong market presence, aided by innovations in delivery methods, patient assistance programs, and strategic licensing efforts that help mitigate the impact of biosimilar competition.

## Key Market Drivers

### Rising Prevalence of Autoimmune and Chronic Inflammatory Diseases

The increasing incidence of autoimmune and chronic inflammatory disorders is a primary factor driving the Global Humira Market. According to the World Health Organization, approximately 18 million people were living with rheumatoid arthritis in 2019, with a 14.1% increase in global age-standardized prevalence since 1990. In the United States alone, psoriasis affects about 3% of the adult population, totaling over 7.5 million individuals.

This expanding patient base fuels the demand for biologic treatments like Humira, especially as healthcare providers are beginning therapy earlier in the disease course to prevent long-term complications. Greater public awareness and advocacy have also contributed to earlier diagnosis and intervention, making advanced immunotherapies more integral to treatment strategies. Humira's long-standing clinical use across multiple therapeutic areas has established it as a trusted option among physicians, reinforcing its continued adoption.

## Key Market Challenges

### Patent Expirations and Loss of Exclusivity

One of the most significant challenges facing the Global Humira Market is the expiration of its key patents and the resulting loss of market exclusivity. AbbVie's Humira enjoyed a dominant position due to robust patent protection, but the introduction of biosimilar adalimumab products has begun to erode its market share. These biosimilars offer similar efficacy at lower prices, prompting healthcare systems—particularly in cost-sensitive regions—to encourage their use as a cost-saving measure.

As biosimilar availability expands, insurers and pharmacy benefit managers are prioritizing them over the originator drug, increasing pressure on prescribers to switch treatments. This competitive shift is changing pricing dynamics and weakening Humira's revenue potential in markets where cost containment and accessibility are key concerns.

## Key Market Trends

## Rising Demand for Real-World Evidence (RWE)

A growing focus on Real-World Evidence (RWE) is shaping the Global Humira Market, as stakeholders seek comprehensive data on how treatments perform outside controlled clinical trials. With the rise of biosimilars and competitive pricing, regulators, payers, and clinicians are relying more on RWE to evaluate long-term outcomes, adherence rates, patient satisfaction, and comparative effectiveness across various populations.

RWE provides valuable insights into how therapies function in real-world settings, especially for patients with multiple conditions or inconsistent treatment patterns. These insights are crucial for making informed decisions about therapy options, reimbursement policies, and value-based care initiatives, particularly as the market adapts to increasing biosimilar usage.

## Key Market Players

Alvotech

Amgen Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

CELLTRION INC.

Coherus BioSciences, Inc.

Fresenius Kabi AG

FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.

Pfizer Inc.

Samsung Bioepis Co., Ltd.

Sandoz Inc.

## Report Scope:

In this report, the Global Humira Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

### Humira Market, By Product:

Branded

Biosimilar

### Humira Market, By Application:

Rheumatoid Arthritis (RA)

Psoriatic Arthritis (PsA)

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Ankylosing Spondylitis

Others

### Humira Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

### Humira Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

## Competitive Landscape

**Company Profiles:** Detailed analysis of the major companies present in the Global Humira Market.

## Available Customizations:

Global Humira Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

## Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends

### 4. VOICE OF CUSTOMER

### 5. GLOBAL HUMIRA MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Product (Branded, Biosimilar)
  - 5.2.2. By Application (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis (UC), Ankylosing Spondylitis, Others)
  - 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)

Pharmacies)

5.2.4. By Company (2024)

5.2.5. By Region

5.3. Market Map

## **6. NORTH AMERICA HUMIRA MARKET OUTLOOK**

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Product

6.2.2. By Application

6.2.3. By Distribution Channel

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Humira Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Product

6.3.1.2.2. By Application

6.3.1.2.3. By Distribution Channel

6.3.2. Mexico Humira Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Product

6.3.2.2.2. By Application

6.3.2.2.3. By Distribution Channel

6.3.3. Canada Humira Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Product

6.3.3.2.2. By Application

6.3.3.2.3. By Distribution Channel

## **7. EUROPE HUMIRA MARKET OUTLOOK**

- 7.1. Market Size & Forecast
  - 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Product
  - 7.2.2. By Application
  - 7.2.3. By Distribution Channel
  - 7.2.4. By Country
- 7.3. Europe: Country Analysis
  - 7.3.1. France Humira Market Outlook
    - 7.3.1.1. Market Size & Forecast
      - 7.3.1.1.1. By Value
    - 7.3.1.2. Market Share & Forecast
      - 7.3.1.2.1. By Product
      - 7.3.1.2.2. By Application
      - 7.3.1.2.3. By Distribution Channel
  - 7.3.2. Germany Humira Market Outlook
    - 7.3.2.1. Market Size & Forecast
      - 7.3.2.1.1. By Value
    - 7.3.2.2. Market Share & Forecast
      - 7.3.2.2.1. By Product
      - 7.3.2.2.2. By Application
      - 7.3.2.2.3. By Distribution Channel
  - 7.3.3. United Kingdom Humira Market Outlook
    - 7.3.3.1. Market Size & Forecast
      - 7.3.3.1.1. By Value
    - 7.3.3.2. Market Share & Forecast
      - 7.3.3.2.1. By Product
      - 7.3.3.2.2. By Application
      - 7.3.3.2.3. By Distribution Channel
  - 7.3.4. Italy Humira Market Outlook
    - 7.3.4.1. Market Size & Forecast
      - 7.3.4.1.1. By Value
    - 7.3.4.2. Market Share & Forecast
      - 7.3.4.2.1. By Product
      - 7.3.4.2.2. By Application
      - 7.3.4.2.3. By Distribution Channel
  - 7.3.5. Spain Humira Market Outlook
    - 7.3.5.1. Market Size & Forecast
      - 7.3.5.1.1. By Value

- 7.3.5.2. Market Share & Forecast
  - 7.3.5.2.1. By Product
  - 7.3.5.2.2. By Application
  - 7.3.5.2.3. By Distribution Channel

## **8. ASIA-PACIFIC HUMIRA MARKET OUTLOOK**

- 8.1. Market Size & Forecast
  - 8.1.1. By Value
- 8.2. Market Share & Forecast
  - 8.2.1. By Product
  - 8.2.2. By Application
  - 8.2.3. By Distribution Channel
  - 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
  - 8.3.1. China Humira Market Outlook
    - 8.3.1.1. Market Size & Forecast
      - 8.3.1.1.1. By Value
    - 8.3.1.2. Market Share & Forecast
      - 8.3.1.2.1. By Product
      - 8.3.1.2.2. By Application
      - 8.3.1.2.3. By Distribution Channel
  - 8.3.2. India Humira Market Outlook
    - 8.3.2.1. Market Size & Forecast
      - 8.3.2.1.1. By Value
    - 8.3.2.2. Market Share & Forecast
      - 8.3.2.2.1. By Product
      - 8.3.2.2.2. By Application
      - 8.3.2.2.3. By Distribution Channel
  - 8.3.3. South Korea Humira Market Outlook
    - 8.3.3.1. Market Size & Forecast
      - 8.3.3.1.1. By Value
    - 8.3.3.2. Market Share & Forecast
      - 8.3.3.2.1. By Product
      - 8.3.3.2.2. By Application
      - 8.3.3.2.3. By Distribution Channel
  - 8.3.4. Japan Humira Market Outlook
    - 8.3.4.1. Market Size & Forecast
      - 8.3.4.1.1. By Value

- 8.3.4.2. Market Share & Forecast
  - 8.3.4.2.1. By Product
  - 8.3.4.2.2. By Application
  - 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Humira Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Application
    - 8.3.5.2.3. By Distribution Channel

## **9. SOUTH AMERICA HUMIRA MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Product
  - 9.2.2. By Application
  - 9.2.3. By Distribution Channel
  - 9.2.4. By Country
- 9.3. South America: Country Analysis
  - 9.3.1. Brazil Humira Market Outlook
    - 9.3.1.1. Market Size & Forecast
      - 9.3.1.1.1. By Value
    - 9.3.1.2. Market Share & Forecast
      - 9.3.1.2.1. By Product
      - 9.3.1.2.2. By Application
      - 9.3.1.2.3. By Distribution Channel
  - 9.3.2. Argentina Humira Market Outlook
    - 9.3.2.1. Market Size & Forecast
      - 9.3.2.1.1. By Value
    - 9.3.2.2. Market Share & Forecast
      - 9.3.2.2.1. By Product
      - 9.3.2.2.2. By Application
      - 9.3.2.2.3. By Distribution Channel
  - 9.3.3. Colombia Humira Market Outlook
    - 9.3.3.1. Market Size & Forecast
      - 9.3.3.1.1. By Value

### 9.3.3.2. Market Share & Forecast

#### 9.3.3.2.1. By Product

#### 9.3.3.2.2. By Application

#### 9.3.3.2.3. By Distribution Channel

## **10. MIDDLE EAST AND AFRICA HUMIRA MARKET OUTLOOK**

### 10.1. Market Size & Forecast

#### 10.1.1. By Value

### 10.2. Market Share & Forecast

#### 10.2.1. By Product

#### 10.2.2. By Application

#### 10.2.3. By Distribution Channel

#### 10.2.4. By Country

### 10.3. MEA: Country Analysis

#### 10.3.1. South Africa Humira Market Outlook

##### 10.3.1.1. Market Size & Forecast

###### 10.3.1.1.1. By Value

##### 10.3.1.2. Market Share & Forecast

###### 10.3.1.2.1. By Product

###### 10.3.1.2.2. By Application

###### 10.3.1.2.3. By Distribution Channel

#### 10.3.2. Saudi Arabia Humira Market Outlook

##### 10.3.2.1. Market Size & Forecast

###### 10.3.2.1.1. By Value

##### 10.3.2.2. Market Share & Forecast

###### 10.3.2.2.1. By Product

###### 10.3.2.2.2. By Application

###### 10.3.2.2.3. By Distribution Channel

#### 10.3.3. UAE Humira Market Outlook

##### 10.3.3.1. Market Size & Forecast

###### 10.3.3.1.1. By Value

##### 10.3.3.2. Market Share & Forecast

###### 10.3.3.2.1. By Product

###### 10.3.3.2.2. By Application

###### 10.3.3.2.3. By Distribution Channel

## **11. MARKET DYNAMICS**

- 11.1. Drivers
- 11.2. Challenges

## **12. MARKET TRENDS & DEVELOPMENTS**

- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments

## **13. DISRUPTIONS: CONFLICTS, PANDEMICS AND TRADE BARRIERS**

## **14. PORTERS FIVE FORCES ANALYSIS**

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products

## **15. COMPETITIVE LANDSCAPE**

- 15.1. Alvotech
  - 15.1.1. Business Overview
  - 15.1.2. Company Snapshot
  - 15.1.3. Products & Services
  - 15.1.4. Financials (As Reported)
  - 15.1.5. Recent Developments
  - 15.1.6. Key Personnel Details
  - 15.1.7. SWOT Analysis
- 15.2. Amgen Inc.
- 15.3. Boehringer Ingelheim Pharmaceuticals, Inc.
- 15.4. CELLTRION INC.
- 15.5. Coherus BioSciences, Inc.
- 15.6. Fresenius Kabi AG
- 15.7. FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
- 15.8. Pfizer Inc.
- 15.9. Samsung Bioepis Co., Ltd.
- 15.10. Sandoz Inc.

## **16. STRATEGIC RECOMMENDATIONS**

## **17. ABOUT US & DISCLAIMER**

## I would like to order

Product name: Humira Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Branded, Biosimilar), By Application (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis (UC), Ankylosing Spondylitis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition, 2020-2030F

Product link: <https://marketpublishers.com/r/HA8131C57B47EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HA8131C57B47EN.html>